Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy
暂无分享,去创建一个
C. Akdis | K. Ruxrungtham | S. Sirivichayakul | M. Akdiş | M. Sokolowska | W. Kwok | M. Wawrzyniak | A. Sangasapaviliya | B. Rückert | J. I. Kast | H. Morita | P. Thantiworasit | T. Boonpiyathad | Panitan Pradubpongsa | Rattanaporn Fuengthong | Jeannette I. Kast
[1] M. Steffensen,et al. A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group , 2018, Allergy.
[2] D. Barber,et al. Persistent regulatory T‐cell response 2 years after 3 years of grass tablet SLIT: Links to reduced eosinophil counts, sIgE levels, and clinical benefit , 2018, Allergy.
[3] C. Bachert,et al. Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma , 2018, Allergy.
[4] Y. Okamoto,et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy‐tablet in Japanese children , 2018, Allergy.
[5] H. Sampson,et al. Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut‐sensitized mice , 2018, Allergy.
[6] M. Akdiş,et al. Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[7] S. Kim,et al. Allergen‐specific immunotherapy induces regulatory T cells in an atopic dermatitis mouse model , 2018, Allergy.
[8] Y. Okamoto,et al. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy , 2018, Allergy.
[9] H. Lou,et al. Efficacy and safety of subcutaneous immunotherapy with house dust mite for allergic rhinitis: A Meta‐analysis of Randomized Controlled Trials , 2018, Allergy.
[10] C. Bachert,et al. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial , 2018, Allergy.
[11] K. Bergmann,et al. New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen‐induced allergic rhinitis , 2018, Allergy.
[12] O. Pfaar,et al. Clinical trials in allergen immunotherapy: current concepts and future needs , 2018, Allergy.
[13] A. Sheikh,et al. EAACI guidelines on allergen immunotherapy: Executive statement , 2018, Allergy.
[14] A. Sheikh,et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.
[15] B. Cases,et al. Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice , 2018, Allergy.
[16] C. Akdis,et al. Microbiome and asthma , 2018, Asthma Research and Practice.
[17] A. Togias,et al. Synchronous immune alterations mirror clinical response during allergen immunotherapy , 2017, The Journal of allergy and clinical immunology.
[18] R. Valenta,et al. House dust mites as potential carriers for IgE sensitization to bacterial antigens , 2017, Allergy.
[19] P. Linsley,et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders , 2017, Science Translational Medicine.
[20] P Demoly,et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper , 2017, Allergy.
[21] E. d'Hennezel,et al. Suppression by human FOXP3+ regulatory T cells requires FOXP3-TIP60 interactions , 2017, Science Immunology.
[22] J. Shelhamer,et al. Dysregulation of lipidomic profile and antiviral immunity in response to hyaluronan in patients with severe asthma. , 2017, The Journal of allergy and clinical immunology.
[23] K. Ruxrungtham,et al. High‐dose bee venom exposure induces similar tolerogenic B‐cell responses in allergic patients and healthy beekeepers , 2017, Allergy.
[24] A. Togias,et al. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial , 2017, JAMA.
[25] S. Durham,et al. SATB1 is repressed in FoxP3+Tregs following Grass Pollen Subcutaneous and Sublingual Immunotherapy and Correlates with Clinical efficacy , 2017 .
[26] M. Akdiş,et al. Role of regulatory B cells in immune tolerance to allergens and beyond. , 2016, The Journal of allergy and clinical immunology.
[27] W. Lehmacher,et al. A 12‐week DBPC dose‐finding study with sublingual monomeric allergoid tablets in house dust mite‐allergic patients , 2016, Allergy.
[28] R. Van Ree,et al. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. , 2016, The Journal of allergy and clinical immunology.
[29] C. Akdis,et al. A novel, dual cytokine‐secretion assay for the purification of human Th22 cells that do not co‐produce IL‐17A , 2016, Allergy.
[30] W. Thomas,et al. Chronic cat allergen exposure induces a TH2 cell-dependent IgG4 response related to low sensitization. , 2015, The Journal of allergy and clinical immunology.
[31] R. Van Ree,et al. International consensus on allergy immunotherapy. , 2015, The Journal of allergy and clinical immunology.
[32] E. Elkord,et al. Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP , 2015, Oncotarget.
[33] C. Akdis,et al. T-cell regulation during viral and nonviral asthma exacerbations. , 2015, The Journal of allergy and clinical immunology.
[34] M. Kubo,et al. Helios Enhances Treg Cell Function in Cooperation With FoxP3 , 2015, Arthritis & rheumatology.
[35] Cezmi A Akdis,et al. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens , 2015, The World Allergy Organization journal.
[36] A. Togias,et al. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge , 2015, Allergy.
[37] C. Akdis,et al. Advances in allergen immunotherapy: Aiming for complete tolerance to allergens , 2015, Science Translational Medicine.
[38] H. Schild,et al. Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo , 2015, Nature Immunology.
[39] C. Akdis,et al. Scientific foundations of allergen-specific immunotherapy for allergic disease. , 2014, Chest.
[40] C. Akdis,et al. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. , 2014, The Journal of allergy and clinical immunology.
[41] Stephen J Galli,et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). , 2014, The Journal of allergy and clinical immunology.
[42] E. James,et al. Characterization of CD4+ T cell subsets in allergy. , 2012, Current opinion in immunology.
[43] E. James,et al. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. , 2012, The Journal of allergy and clinical immunology.
[44] U. Beier,et al. Helios Expression Is a Marker of T Cell Activation and Proliferation , 2011, PloS one.
[45] K. Toellner,et al. Helios Is Associated with CD4 T Cells Differentiating to T Helper 2 and Follicular Helper T Cells In Vivo Independently of Foxp3 Expression , 2011, PloS one.
[46] E. James,et al. Direct ex vivo analysis of allergen-specific CD4+ T cells. , 2010, The Journal of allergy and clinical immunology.
[47] Y. Belkaid,et al. Expression of Helios, an Ikaros Transcription Factor Family Member, Differentiates Thymic-Derived from Peripherally Induced Foxp3+ T Regulatory Cells , 2010, The Journal of Immunology.
[48] C. Akdis,et al. Therapeutic manipulation of immune tolerance in allergic disease , 2009, Nature Reviews Drug Discovery.
[49] Lisa C. Zaba,et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.
[50] S. Durham,et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. , 2008, The Journal of allergy and clinical immunology.
[51] B. Bohle,et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. , 2007, The Journal of allergy and clinical immunology.
[52] K. Asadullah,et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.
[53] K. Asadullah,et al. IL-22 increases the innate immunity of tissues. , 2004, Immunity.
[54] S. Durham,et al. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.
[55] Marek Jutel,et al. IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy , 2003, European journal of immunology.
[56] C. Akdis,et al. Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.